Self-Assembled, Adjuvant/Antigen-Based Nanovaccine Mediates Anti-Tumor Immune Response Against Melanoma Tumor

Rajendrakumar, Santhosh Kalash; Mohapatra, Adityanarayan; Singh, Bijay; Cho, Chong‐Su; Park, Inkyu

doi:10.20944/preprints201807.0561.v1

Cited by 4 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Effector T cells were prepared and purified using a nylon column method as previously described. 55,56 Collected effector T cells were labeled with 2 μM carboxyfluorescein succinimidyl ester (CFSE) (BioLegend) for 5 min at room temperature. CT26 cells were labeled with CellTracker Red CMTPX dye (Invitrogen) at room temperature and then cocultured with CFSE-labeled T cells in a 24-well plate at a T cell:target cell ratio of 100:1.…”

Section: Methodsmentioning

confidence: 99%

In Situ Nanoadjuvant-Assembled Tumor Vaccine for Preventing Long-Term Recurrence

et al. 2019

View full text Add to dashboard Cite

Although immune checkpoint inhibitors have emerged as a breakthrough in cancer therapy, a monotherapy approach is not sufficient. Here, we report an immune checkpoint inhibitor-modified nanoparticle for an in situ-assembled tumor vaccine that can activate immune systems in the tumor microenvironment and prevent the long-term recurrence of tumors. Adjuvant-loaded nanoparticles were prepared by entrapping imiquimod (IQ) in photoresponsive polydopamine nanoparticles (IQ/PNs). The surfaces of IQ/PNs were then modified with anti-PDL1 antibody (PDL1Ab-IQ/PNs) for in situ assembly with inactivated tumor cells and immune checkpoint blocking of PDL1 (programmed cell death 1 ligand 1). The presence of anti-PDL1 antibodies on IQ/PNs increased the binding of nanoparticles to CT26 cancer cells overexpressing PDL1. Subsequent near-infrared (NIR) irradiation induced a greater photothermal anticancer effect against cells treated with PDL1Ab-IQ/PNs than cells treated with plain PNs or unmodified IQ/PNs. To mimic the tumor microenvironment, we cocultured bone marrow-derived dendritic cells with CT26 cells treated with various nanoparticle formulations and NIR irradiated. This coculture study revealed that NIR-inactivated, PDL1Ab-IQ/PN-bound CT26 cells induced maturation of dendritic cells to the greatest extent. Following a single intravenous administration of different nanoparticle formulations in CT26 tumor-bearing mice, PDL1Ab-IQ/PNs showed greater tumor tissue accumulation than unmodified nanoparticles. Subsequent NIR irradiation of mice treated with PDL1Ab-IQ/PNs resulted in tumor ablation. In addition to primary tumor ablation, PDL1Ab-IQ/PNs completely prevented the growth of a secondarily challenged CT26 tumor at a distant site, producing 100% survival for up to 150 days. A long-term protection study revealed that treatment with PDL1Ab-IQ/PNs followed by NIR irradiation inhibited the growth of distant, secondarily challenged CT26 tumors 150 days after the first tumor inoculation. Moreover, increased infiltration of T cells was observed in tumor tissues treated with PDL1Ab-IQ/PNs and NIR-irradiated, and T cells isolated from splenocytes of mice in which tumor recurrence was prevented showed active killing of CT26 cells. These results suggest that PDL1Ab-IQ/PNs in conjunction with NIR irradiation induce a potent, in situ-assembled, all-in-one tumor vaccine with adjuvant-containing nanoparticle-bound, inactivated tumor cells. Such in situ nanoadjuvant-assembled tumor vaccines can be further developed for long-term prevention of tumor recurrence without the need for chemotherapy.

show abstract

Section: Methodsmentioning

confidence: 99%

In Situ Nanoadjuvant-Assembled Tumor Vaccine for Preventing Long-Term Recurrence

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Nanoparticle-based biomaterials have a critical role in cancer immunotherapy compared with conventional drugs [39]. Immunotherapy often targets tumor cells, immune and stromal cells in the tumor microenvironment [40]. Additionally, side reactions occurring due to the interactions between nanoparticles (NPs) and cells can be adjusted by modifications of nanoparticles [41].…”

Section: Nanoparticles In Cancer Immunotherapymentioning

confidence: 99%

Immune System Modulations in Cancer Treatment: Nanoparticles in Immunotherapy

Kızılbey¹,

Türkoğlu²,

Kırmızıtaş³

2021

Cell Interaction - Molecular and Immunological Basis for Disease Management

View full text Add to dashboard Cite

Cancer immunotherapy is based on the idea of overcoming the main problems in the traditional cancer treatments and enhancing the patient’s long-term survival and quality of life. Immunotherapy methods aimed to influence the immune system, to detect and eradicate the tumors site and predict the potential results. Nowadays, nanomaterials-based immunotherapy approaches are gaining interest due to numerous advantages like their ability to target cells and tissues directly and reduce the off-target toxicity. Therefore, topics about immune system components, nanomaterials, their usage in immunotherapy and the benefits they provide will be discussed in this presented book chapter. Immunotherapy can be divided into two groups mainly; active and passive immunotherapy including their subtitles such as immune checkpoint inhibitors, adoptive immunotherapy, CAR-T therapies, vaccines, and monoclonal antibodies. Main classification and the methods will be evaluated. Furthermore, state-of-art nanocarriers based immunotherapy methods will be mentioned in detail. The terms of size, charge, material type and surface modifications of the nanoparticles will be reviewed to understand the interference of immune system and nanoparticles and their advantages/disadvantages in immunotherapy systems.

show abstract

Bioactive Nanoparticles for Cancer Immunotherapy

Surendran

Moon

Park

et al. 2018

IJMS

View full text Add to dashboard Cite

Currently, immunotherapy is considered to be one of the effective treatment modalities for cancer. All the developments and discoveries in this field up to the recent Nobel Prize add to the interest for research into this vast area of study. Targeting tumor environment as well as the immune system is a suitable strategy to be applied for cancer treatment. Usage of nanoparticle systems for delivery of immunotherapeutic agents to the body being widely studied and found to be a promising area of research to be considered and investigated further. Nanoparticles for immunotherapy would be one of the effective treatment options for cancer therapy in the future due to their high specificity, efficacy, ability to diagnose, imaging, and therapeutic effect. Among the many nanoparticle systems, polylactic-co-glycolic acid (PLGA) nanoparticles, liposomes, micelles, gold nanoparticles, iron oxide, dendrimers, and artificial exosomes are widely used for immunotherapy of cancer. Moreover, the combination therapy found to be the more effective way of treating the tumor. Here, we review the current trends in nanoparticle therapy and efficiency of these nanosystems in delivering antigens, adjuvants, therapeutic drugs, and other immunotherapeutic agents. This review summarizes the currently available bioactive nanoparticle systems for cancer immunotherapy.

show abstract

Self-Assembled, Adjuvant/Antigen-Based Nanovaccine Mediates Anti-Tumor Immune Response Against Melanoma Tumor

Cited by 4 publications

References 36 publications

In Situ Nanoadjuvant-Assembled Tumor Vaccine for Preventing Long-Term Recurrence

In Situ Nanoadjuvant-Assembled Tumor Vaccine for Preventing Long-Term Recurrence

Immune System Modulations in Cancer Treatment: Nanoparticles in Immunotherapy

Bioactive Nanoparticles for Cancer Immunotherapy

Contact Info

Product

Resources

About